Aquestive Therapeutics Stock Price To Book

AQST Stock

USD 4.81 0.25 5.48%

Aquestive Therapeutics fundamentals help investors to digest information that contributes to Aquestive Therapeutics' financial success or failures. It also enables traders to predict the movement of Aquestive Stock. The fundamental analysis module provides a way to measure Aquestive Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aquestive Therapeutics stock.

Other Current Liab Total Assets

Price To Book Ratio is likely to drop to -1.22 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Aquestive Therapeutics Company Price To Book Analysis

Aquestive Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Aquestive Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for Aquestive Therapeutics is extremely important. It helps to project a fair market value of Aquestive Stock properly, considering its historical fundamentals such as Price To Book. Since Aquestive Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aquestive Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aquestive Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock	Good Will
Total Assets		-0.22	0.29	-0.38	0.88	0.64	0.27	0.57	-0.49	0.99	-0.44	-0.34	-0.82	-0.34	0.04	-0.8	-0.82	0.64	-0.15	0.75	-0.15	0.75	0.35	-0.15
Total Stockholder Equity	-0.22		0.56	0.98	0.0	0.01	0.09	-0.87	0.37	-0.17	0.33	-0.43	0.59	0.63	-0.71	0.0	0.43	-0.77	0.58	0.39	0.58	0.25	-0.9	0.58
Net Tangible Assets	0.29	0.56		0.52	0.31	-0.09	-0.28	-0.34	-0.54	0.38	-0.44	-0.01	-0.25	-0.24	-0.51	-0.56	-0.35	-0.04	0.25	0.78	0.25	0.7	-0.3	0.25
Retained Earnings	-0.38	0.98	0.52		-0.12	-0.16	-0.06	-0.91	0.4	-0.32	0.34	-0.3	0.67	0.61	-0.66	0.11	0.52	-0.82	0.6	0.26	0.6	0.08	-0.91	0.6
Accounts Payable	0.88	0.0	0.31	-0.12		0.54	0.11	0.33	-0.26	0.88	-0.32	-0.29	-0.56	-0.05	0.09	-0.79	-0.69	0.37	-0.07	0.71	-0.07	0.64	0.13	-0.07
Long Term Debt	0.64	0.01	-0.09	-0.16	0.54		0.75	0.23	0.13	0.63	0.03	-0.72	-0.26	0.15	-0.14	-0.17	-0.18	0.21	0.05	0.48	0.05	0.5	-0.08	0.05
Net Receivables	0.27	0.09	-0.28	-0.06	0.11	0.75		0.06	0.33	0.23	0.48	-0.72	0.04	0.38	-0.32	0.12	0.08	-0.08	0.09	0.15	0.09	0.28	-0.12	0.09
Total Liab	0.57	-0.87	-0.34	-0.91	0.33	0.23	0.06		-0.44	0.52	-0.39	0.13	-0.77	-0.63	0.61	-0.25	-0.62	0.92	-0.29	0.01	-0.29	0.07	0.87	-0.29
Short Long Term Debt	-0.49	0.37	-0.54	0.4	-0.26	0.13	0.33	-0.44		-0.54	0.8	-0.41	0.83	0.89	-0.08	0.62	0.8	-0.68	0.41	-0.42	0.41	-0.56	-0.56	0.41
Total Current Assets	0.99	-0.17	0.38	-0.32	0.88	0.63	0.23	0.52	-0.54		-0.48	-0.31	-0.81	-0.36	0.02	-0.81	-0.83	0.62	-0.14	0.8	-0.14	0.8	0.32	-0.14
Short Term Debt	-0.44	0.33	-0.44	0.34	-0.32	0.03	0.48	-0.39	0.8	-0.48		-0.33	0.66	0.82	-0.32	0.55	0.57	-0.7	0.36	-0.36	0.36	-0.49	-0.47	0.36
Intangible Assets	-0.34	-0.43	-0.01	-0.3	-0.29	-0.72	-0.72	0.13	-0.41	-0.31	-0.33		-0.14	-0.46	0.55	0.06	-0.15	0.2	-0.48	-0.44	-0.48	-0.34	0.51	-0.48
Common Stock	-0.82	0.59	-0.25	0.67	-0.56	-0.26	0.04	-0.77	0.83	-0.81	0.66	-0.14		0.78	-0.24	0.68	0.94	-0.88	0.39	-0.48	0.39	-0.55	-0.71	0.39
Property Plant Equipment	-0.34	0.63	-0.24	0.61	-0.05	0.15	0.38	-0.63	0.89	-0.36	0.82	-0.46	0.78		-0.3	0.32	0.63	-0.83	0.37	-0.15	0.37	-0.26	-0.69	0.37
Current Deferred Revenue	0.04	-0.71	-0.51	-0.66	0.09	-0.14	-0.32	0.61	-0.08	0.02	-0.32	0.55	-0.24	-0.3		0.02	-0.14	0.55	-0.43	-0.43	-0.43	-0.32	0.74	-0.43
Net Debt	-0.8	0.0	-0.56	0.11	-0.79	-0.17	0.12	-0.25	0.62	-0.81	0.55	0.06	0.68	0.32	0.02		0.83	-0.42	0.28	-0.7	0.28	-0.76	-0.24	0.28
Long Term Debt Total	-0.82	0.43	-0.35	0.52	-0.69	-0.18	0.08	-0.62	0.8	-0.83	0.57	-0.15	0.94	0.63	-0.14	0.83		-0.71	0.43	-0.53	0.43	-0.6	-0.59	0.43
Capital Surpluse	0.64	-0.77	-0.04	-0.82	0.37	0.21	-0.08	0.92	-0.68	0.62	-0.7	0.2	-0.88	-0.83	0.55	-0.42	-0.71		-0.35	0.21	-0.35	0.31	0.85	-0.35
Deferred Long Term Liab	-0.15	0.58	0.25	0.6	-0.07	0.05	0.09	-0.29	0.41	-0.14	0.36	-0.48	0.39	0.37	-0.43	0.28	0.43	-0.35		0.29	1.0	-0.06	-0.58	1.0
Net Invested Capital	0.75	0.39	0.78	0.26	0.71	0.48	0.15	0.01	-0.42	0.8	-0.36	-0.44	-0.48	-0.15	-0.43	-0.7	-0.53	0.21	0.29		0.29	0.88	-0.19	0.29
Long Term Investments	-0.15	0.58	0.25	0.6	-0.07	0.05	0.09	-0.29	0.41	-0.14	0.36	-0.48	0.39	0.37	-0.43	0.28	0.43	-0.35	1.0	0.29		-0.06	-0.58	1.0
Net Working Capital	0.75	0.25	0.7	0.08	0.64	0.5	0.28	0.07	-0.56	0.8	-0.49	-0.34	-0.55	-0.26	-0.32	-0.76	-0.6	0.31	-0.06	0.88	-0.06		0.02	-0.06
Capital Stock	0.35	-0.9	-0.3	-0.91	0.13	-0.08	-0.12	0.87	-0.56	0.32	-0.47	0.51	-0.71	-0.69	0.74	-0.24	-0.59	0.85	-0.58	-0.19	-0.58	0.02		-0.58
Good Will	-0.15	0.58	0.25	0.6	-0.07	0.05	0.09	-0.29	0.41	-0.14	0.36	-0.48	0.39	0.37	-0.43	0.28	0.43	-0.35	1.0	0.29	1.0	-0.06	-0.58

Click cells to compare fundamentals

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Competition

Predict Aquestive Therapeutics

Price Book Value Ratio Over Time

Aquestive Book Value Per Share

Book Value Per Share

(1.83)

At this time, Aquestive Therapeutics' Book Value Per Share is comparatively stable compared to the past year.

Based on the latest financial disclosure, Aquestive Therapeutics has a Price To Book of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The price to book for all United States stocks is 100.0% higher than that of the company.

Aquestive Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aquestive Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aquestive Therapeutics could also be used in its relative valuation, which is a method of valuing Aquestive Therapeutics by comparing valuation metrics of similar companies.

Aquestive Therapeutics is currently under evaluation in price to book category among its peers.

Aquestive Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Aquestive Therapeutics from analyzing Aquestive Therapeutics' financial statements. These drivers represent accounts that assess Aquestive Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aquestive Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	147.6M	180.0M	148.1M	44.0M	123.7M	141.9M
Enterprise Value	158.6M	188.7M	176.5M	72.8M	133.2M	155.3M

Aquestive Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aquestive Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aquestive Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Aquestive Fundamentals

	Return On Asset	-0.16
	Profit Margin	(0.60) %
	Operating Margin	(0.61) %
	Current Valuation	397.54 M
	Shares Outstanding	91.18 M
	Shares Owned By Insiders	5.00 %
	Shares Owned By Institutions	52.41 %
	Number Of Shares Shorted	10.14 M
	Price To Earning	(1.90) X
	Price To Sales	7.45 X
	Revenue	50.58 M
	Gross Profit	28.29 M
	EBITDA	1.18 M
	Net Income	(7.87 M)
	Cash And Equivalents	17.7 M
	Cash Per Share	0.33 X
	Total Debt	33.32 M
	Debt To Equity	468.20 %
	Current Ratio	1.47 X
	Book Value Per Share	(0.50) X
	Cash Flow From Operations	(6.38 M)
	Short Ratio	7.97 X
	Earnings Per Share	(0.48) X
	Target Price	10.06
	Number Of Employees	135
	Beta	2.82
	Market Capitalization	438.57 M
	Total Asset	57.42 M
	Retained Earnings	(319.08 M)
	Working Capital	22.66 M
	Current Asset	38.38 M
	Current Liabilities	17.95 M
	Net Asset	57.42 M

About Aquestive Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Aquestive Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aquestive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aquestive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aquestive Stock Analysis

When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC